This channel includes news on cardiovascular care delivery, including how patients are diagnosed and treated, cardiac care guidelines, policies or legislation impacting patient care, device recalls that may impact patient care, and cardiology practice management.
What good is AI in healthcare if it doesn’t improve financial margins? The question is getting posed in the C-suites of provider organizations and insurance companies.
Three leading medical societies collaborated on the new document, providing detailed recommendations that cover a wide variety of technologies and clinical scenarios.
The new platform provides users with real-time access to high-quality electrocardiograms and patient data. The goal is to ensure everyone is on the same page at all times, with no unnecessary delays.
The annual list is based on resources, services provided, outcomes data and survey responses from thousands of physicians. Did your facility make the cut?
A word to the wise among leaders of hospitals and health systems: Don’t wait on the government to tell you how to keep healthcare AI on track and healthcare providers up to speed.
According to a new proposal, using AI to evaluate CCTA results and quantify plaque buildup is “reasonable and medically necessary” in certain clinical scenarios.
A cardiologist in Billings, Montana, says her new-look practice was designed to reach patients faster and ditch unnecessary red tape. Patients pay an upfront fee, and insurance does not play a role in treatment decisions.
Weighing opportunities vs. challenges presented by AI and automation, business analysts have found Europe and the United States in pretty much the same boat.
Devi Nair, MD, director of cardiac electrophysiology with St. Bernard's Heart and Vascular Center, discussed her experience using a new-look Medtronic pulsed field ablation (PFA) system to treat persistent AFib.
As it continues to become more proficient and increase its reach, healthcare AI will disappoint both those who expect it to produce miracles and those who fear it will cause catastrophes.
Researchers examined data from eight different studies, noting that transcaval TAVR appears to be a "viable alternative" when transfemoral access is not an option. The procedure was linked to an overall success rate of 98.5%.